[go: up one dir, main page]

HUE064818T2 - Dopa dekarboxiláz inhibitor készítmények - Google Patents

Dopa dekarboxiláz inhibitor készítmények

Info

Publication number
HUE064818T2
HUE064818T2 HUE20198371A HUE20198371A HUE064818T2 HU E064818 T2 HUE064818 T2 HU E064818T2 HU E20198371 A HUE20198371 A HU E20198371A HU E20198371 A HUE20198371 A HU E20198371A HU E064818 T2 HUE064818 T2 HU E064818T2
Authority
HU
Hungary
Prior art keywords
decarboxylase inhibitor
inhibitor compositions
dopa decarboxylase
dopa
compositions
Prior art date
Application number
HUE20198371A
Other languages
English (en)
Inventor
Oron Yacoby-Zeevi
Original Assignee
Neuroderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53488380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE064818(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuroderm Ltd filed Critical Neuroderm Ltd
Publication of HUE064818T2 publication Critical patent/HUE064818T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE20198371A 2014-03-13 2015-03-12 Dopa dekarboxiláz inhibitor készítmények HUE064818T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461952477P 2014-03-13 2014-03-13
US201461990967P 2014-05-09 2014-05-09

Publications (1)

Publication Number Publication Date
HUE064818T2 true HUE064818T2 (hu) 2024-04-28

Family

ID=53488380

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE15731727A HUE052642T2 (hu) 2014-03-13 2015-03-12 DOPA dekarboxiláz inhibitor készítmények
HUE20198371A HUE064818T2 (hu) 2014-03-13 2015-03-12 Dopa dekarboxiláz inhibitor készítmények

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE15731727A HUE052642T2 (hu) 2014-03-13 2015-03-12 DOPA dekarboxiláz inhibitor készítmények

Country Status (19)

Country Link
US (4) US10022320B2 (hu)
EP (3) EP3777833B1 (hu)
JP (2) JP6591995B2 (hu)
CN (1) CN106413754B (hu)
AU (1) AU2015228369B2 (hu)
BR (1) BR112016021034A8 (hu)
CA (1) CA2942244C (hu)
DK (2) DK3116475T3 (hu)
ES (2) ES2836325T3 (hu)
FI (1) FI3777833T3 (hu)
HR (2) HRP20201948T1 (hu)
HU (2) HUE052642T2 (hu)
IL (1) IL247668B (hu)
MX (1) MX2016011837A (hu)
PL (2) PL3777833T3 (hu)
PT (2) PT3777833T (hu)
RS (1) RS65060B1 (hu)
RU (1) RU2684105C2 (hu)
WO (1) WO2015136538A1 (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3777839A1 (en) 2009-05-19 2021-02-17 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
NZ610911A (en) 2010-11-15 2015-02-27 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
EP3777833B1 (en) 2014-03-13 2023-10-18 Neuroderm Ltd. Dopa decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
EP3183008B1 (en) 2015-09-30 2019-06-26 Duke University Ascorbate formulations and methods of use as contrast agents
WO2018154447A1 (en) * 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
AU2019379806B2 (en) 2018-11-15 2025-08-14 Abbvie Inc. Pharmaceutical formulations for subcutaneous administration
WO2020178810A1 (en) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
CN111701024B (zh) * 2020-05-26 2022-05-24 上海京新生物医药有限公司 一种左旋多巴制剂及其制备方法及其应用
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
CN113396897B (zh) * 2021-07-26 2022-06-07 苏州华测生物技术有限公司 一种稳定生物基质中卡比多巴/左旋多巴的方法
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3769424A (en) 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
AU6889274A (en) 1973-05-17 1975-11-20 Astra Laekemedel Ab Treatment of neurological disorders
US3936495A (en) 1973-11-27 1976-02-03 Merck & Co., Inc. Purification process
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4241082A (en) 1977-09-02 1980-12-23 Sankyo Company Limited Agents for promoting reproductive ability of domestic animals
JPS5450700A (en) 1977-09-28 1979-04-20 Sankyo Co Glazing agent of animal leather
JPS6021570B2 (ja) 1978-07-04 1985-05-28 三共株式会社 ド−パ類の高濃度製剤の製法
JPS56115749A (en) 1980-02-18 1981-09-11 Sagami Chem Res Center Dopa derivative
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4642316A (en) 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
DE252290T1 (de) 1986-06-10 1988-06-09 Chiesi Farmaceutici S.P.A., Parma Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US4832957A (en) 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4684666A (en) 1986-08-19 1987-08-04 Haas Pharmaceuticals, Inc. Stabilized liquid analgesic compositions
IT1226902B (it) 1988-07-12 1991-02-21 Mini Ricerca Scient Tecnolog Processo per la sintesi del levodopa
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
WO1992007561A1 (en) 1990-10-30 1992-05-14 Ss Pharmaceutical Co., Ltd. Antiphlogistic and analgesic gel preparation
US5877176A (en) 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
CA2143070C (en) 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
US6258827B1 (en) 1995-05-26 2001-07-10 Pfizer Inc. Combinations for the treatment of parkinsonism containing selective NMDA antagonists
GB9523833D0 (en) 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
IL119417A (en) 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US6245917B1 (en) 1998-03-20 2001-06-12 Warner-Lambert Company Crystalline sodium phenytoin monohydrate
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
CN1303991C (zh) 1998-05-15 2007-03-14 沃尼尔·朗伯公司 γ－氨基丁酸衍生物的稳定药物制剂和其制备方法
US6274168B1 (en) 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
AU3490300A (en) 1999-03-12 2000-10-04 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US7479498B2 (en) 1999-08-23 2009-01-20 Phoenix Biosciences, Inc. Treatments for viral infections
US6348965B1 (en) 1999-09-24 2002-02-19 Henry Palladino Solid state fluorescence and absorption spectroscopy
SE0001151D0 (sv) 2000-03-31 2000-03-31 Amarin Dev Ab Method for producing a controlled-release composition
US20020028799A1 (en) 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction
GB0017387D0 (en) 2000-07-14 2000-08-30 Pfizer Ltd Novel enzyme
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US20030119714A1 (en) 2000-12-15 2003-06-26 Naylor Alasdair Mark Treatment of male sexual dysfunction
ATE354573T1 (de) 2000-12-21 2007-03-15 Vertex Pharma ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß
IL159812A0 (en) 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
RU2292871C2 (ru) 2001-10-19 2007-02-10 Айдекс Лэборэтериз, Инк. Инъецируемые композиции для контролируемой доставки фармакологически активного соединения
WO2003050261A2 (en) 2001-12-10 2003-06-19 Bristol-Myers Squibb Company (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
ES2189682B1 (es) 2001-12-11 2004-04-01 Laboratorios Del Dr. Esteve, S.A. Preparacion bebible que comprende ketoprofeno y su empleo en el tratamiento de procesos que cursan con fiebre, inflamacion y/o dolor, en un colectivo de animales, de forma simultanea.
WO2003084514A1 (en) 2002-04-11 2003-10-16 Ranbaxy Laboratories Limited Controlled release pharmaceutical compositions of carbidopa and levodopa
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
BR0315221A (pt) 2002-10-10 2005-08-23 Morphochem Ag Komb Chemie Compostos com atividade antibacteriana
WO2004069146A2 (en) 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
JP2007531701A (ja) 2003-07-18 2007-11-08 バクスター・インターナショナル・インコーポレイテッド 制御された相分離により調製される小球状粒子の作製方法、使用および組成物
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
ES2360759T3 (es) * 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
ATE495739T1 (de) * 2003-08-29 2011-02-15 Transform Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
US20050053669A1 (en) 2003-09-05 2005-03-10 Boehringer Ingelheim International Gmbh Administration form for the oral application of poorly soluble acidic and amphorteric drugs
US20050163849A1 (en) 2003-10-31 2005-07-28 Wong Patrick S. Compositions and dosage forms for enhanced absorption of iron
WO2005099678A1 (en) 2004-04-06 2005-10-27 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
WO2006029411A2 (en) 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
WO2006037061A2 (en) 2004-09-28 2006-04-06 Farouk Karoum Compositions and methods of using d-dopa to treat parkinson's disease
AU2005292184A1 (en) 2004-10-01 2006-04-13 The Research Foundation Of State University Of New York Morphine and morphine precursors
EA013161B1 (ru) 2005-06-08 2010-02-26 Орион Корпорейшн Дозированная форма для перорального применения
DE102006021872B4 (de) 2006-05-11 2008-04-17 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101636145B (zh) 2006-05-31 2014-04-23 雅培产品有限公司 长期24小时经肠给予左旋多巴/卡比多巴
PE20080669A1 (es) 2006-09-08 2008-07-18 Drugtech Corp Composicion de liberacion sostenida que comprende levodopa
CA2606658A1 (en) 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
CA2682888A1 (en) 2007-04-06 2008-10-16 Transform Pharmaceuticals, Inc. Systems and methods for delivering a fluid drug
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
AU2009211028B2 (en) * 2008-02-06 2013-12-05 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
CN101669925B (zh) 2008-09-10 2011-08-10 天津药物研究院 干粉吸入剂、其制备方法和用途
WO2010055133A1 (en) 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
EP3777839A1 (en) 2009-05-19 2021-02-17 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
CN101987081B (zh) 2010-07-16 2012-08-08 钟术光 一种控释制剂
KR101187064B1 (ko) 2010-07-18 2012-09-28 주식회사 바이오폴리메드 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체
US10150792B2 (en) 2010-11-08 2018-12-11 Synthonics, Inc. Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
TR201808178T4 (tr) 2010-11-15 2018-07-23 Neuroderm Ltd Aktif ajanların transdermal dağıtımı için bileşimler.
NZ610911A (en) 2010-11-15 2015-02-27 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
BR112013014304A2 (pt) 2010-12-10 2016-07-19 Synagile Corp composições de pró-fármaco levodopa infundíveis subcutaneamente e método de infusão
WO2013061161A2 (en) 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
TR201204839A2 (tr) * 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
EP2854764B1 (en) 2012-06-05 2018-12-12 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
US20150217046A1 (en) 2012-06-05 2015-08-06 Synagile Corporation Dosing regimens for subcutaneously infusible acidic compositions
US20160022573A1 (en) * 2013-03-13 2016-01-28 Neuroderm, Ltd. Method for treatment of parkinson's disease
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
EP3777833B1 (en) 2014-03-13 2023-10-18 Neuroderm Ltd. Dopa decarboxylase inhibitor compositions
CA2965379A1 (en) 2014-10-21 2016-04-28 Abbvie Inc. Carbidopa and l-dopa prodrugs and methods of use
AU2016358511A1 (en) 2015-11-24 2018-06-21 Neuroderm Ltd. Pharmaceutical compositions comprising levodopa amide and uses thereof
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
WO2019038638A1 (en) 2017-08-21 2019-02-28 Neuroderm Ltd PROCESS FOR PREPARING AMIDE OF PURIFIED LEVODOPA
AR112472A1 (es) 2017-08-21 2019-10-30 Neuroderm Ltd Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas
AR112683A1 (es) 2017-08-21 2019-11-27 Neuroderm Ltd Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprende

Also Published As

Publication number Publication date
DK3116475T3 (da) 2020-12-07
US20210038505A1 (en) 2021-02-11
EP4299128A3 (en) 2024-04-17
US20190151233A1 (en) 2019-05-23
IL247668B (en) 2020-09-30
CA2942244A1 (en) 2015-09-17
HRP20231716T1 (hr) 2024-03-15
US20150352212A1 (en) 2015-12-10
ES2967693T3 (es) 2024-05-03
FI3777833T3 (fi) 2024-01-03
WO2015136538A1 (en) 2015-09-17
PT3777833T (pt) 2024-01-09
AU2015228369B2 (en) 2020-05-21
JP6591995B2 (ja) 2019-10-16
HUE052642T2 (hu) 2021-05-28
RU2016135952A (ru) 2018-04-13
CN106413754A (zh) 2017-02-15
RU2684105C2 (ru) 2019-04-04
RU2016135952A3 (hu) 2018-09-12
EP3777833B1 (en) 2023-10-18
CN106413754B (zh) 2019-11-29
CA2942244C (en) 2022-08-23
EP3116475B1 (en) 2020-11-04
RS65060B1 (sr) 2024-02-29
US10022320B2 (en) 2018-07-17
EP3116475A1 (en) 2017-01-18
BR112016021034A2 (pt) 2017-08-15
US20230240980A1 (en) 2023-08-03
PL3116475T3 (pl) 2021-02-08
BR112016021034A8 (pt) 2021-06-29
EP3777833A1 (en) 2021-02-17
DK3777833T3 (da) 2023-12-18
ES2836325T3 (es) 2021-06-24
JP6770158B2 (ja) 2020-10-14
US10624839B2 (en) 2020-04-21
JP2020011977A (ja) 2020-01-23
PT3116475T (pt) 2020-12-15
JP2017507973A (ja) 2017-03-23
EP4299128A2 (en) 2024-01-03
PL3777833T3 (pl) 2024-03-25
IL247668A0 (en) 2016-11-30
HRP20201948T1 (hr) 2021-01-22
AU2015228369A1 (en) 2016-10-27
MX2016011837A (es) 2017-04-27

Similar Documents

Publication Publication Date Title
IL277167B (en) Cyclopropylamines as lsd1 inhibitors
IL277299B (en) Cyclopropylamines as lsd1 inhibitors
IL247668A0 (en) Preparations that include dopa decarboxylase inhibitors
SG11201704936SA (en) Corrosion inhibitor compositions for acidizing treatments
IL246362A0 (en) Novel glutaminase inhibitors
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
ZA201704301B (en) Microencapsulated nitrification inhibitor compositions
GB201403536D0 (en) Inhibitor compounds
SI3227325T1 (sl) Selektivni sestavki zaviralcev IL-6-trans-signalizacije
HUE050027T2 (hu) Antioxidáns készítmények
GB201411802D0 (en) Effervescent compositions
IL247921A0 (en) Glutaminase inhibitor compounds, preparations containing them and their uses
GB201408167D0 (en) Compositions
GB201406542D0 (en) Intumescent compositions
IL251479A0 (en) components
GB201420306D0 (en) Compositions
SG11201610860UA (en) Sweetener compositions
GB201401005D0 (en) Inhibitor
GB201501779D0 (en) NONOate compositions
GB201411470D0 (en) Effervescent compositions
GB201419849D0 (en) Compositions
GB201406863D0 (en) Compositions comprising variegin